<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926754</url>
  </required_header>
  <id_info>
    <org_study_id>2016-002367-34</org_study_id>
    <secondary_id>H-16030780</secondary_id>
    <nct_id>NCT03926754</nct_id>
  </id_info>
  <brief_title>Beta 3 Agonist Treatment in Heart Failure-2</brief_title>
  <acronym>BEAT-HF II</acronym>
  <official_title>Beta 3 Agonist Treatment in Heart Failure-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bundgaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg-Frederiksberg Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerød hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bornholm Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal North Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study is to assess the structural and functional cardiac&#xD;
      effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to&#xD;
      severe chronic heart failure (LVEF&lt;35%, NYHA III-IV).&#xD;
&#xD;
      The study is a randomized, placebo-controlled, double-blinded trial in two phases with two&#xD;
      hypotheses:&#xD;
&#xD;
      Chronic study - study A: Long-term treatment (3 months) with the β3 adrenergic receptor&#xD;
      agonist Mirabegron is beneficial in patients with moderate to severe human heart failure&#xD;
&#xD;
      Invasive study - Study B: Administration of Mirabegron in patients with heart failure leads&#xD;
      to an immediate increase in cardiac output at a constant or reduced left ventricular filling&#xD;
      pressure during submaximal exercise&#xD;
&#xD;
      Specific aims&#xD;
&#xD;
        1. Determine safety of administration of Mirabegron to patients with moderate to severe&#xD;
           heart failure.&#xD;
&#xD;
        2. Determine if treatment with Mirabegron for 3 months induces beneficial cardiac&#xD;
           structural remodelling in patients with moderate to severe heart failure. In an&#xD;
           open-label follow-up to determine the effects of Mirabegron after an extended duration&#xD;
           (a total of 12 months).&#xD;
&#xD;
        3. Determine if Mirabegron improves symptoms and exercise capacity as indicated by&#xD;
           questionnaires and 6 min walk test in patients with moderate to severe heart failure.&#xD;
&#xD;
        4. Determine effects of Mirabegron on cardiac conduction, repolarisation and rhythms and&#xD;
           arrhythmias in patients with moderate to severe heart failure.&#xD;
&#xD;
        5. Determine effects of Mirabegron on circulating biomarkers in patients with moderate to&#xD;
           severe heart failure.&#xD;
&#xD;
        6. Determine the immediate and short term haemodynamic effects of Mirabron as measured by&#xD;
           CT and invasively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in left ventricular ejection fraction as measured by computed tomography</measure>
    <time_frame>3 months</time_frame>
    <description>Study A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in invasive hemodynamics assesses by right heart catherization</measure>
    <time_frame>At 3 hours and at 1 week</time_frame>
    <description>Study B is explorative assessing the effect on invasive parameters including cardiac output, pulmonary wedge pressure and pulmonary and systemic vascular resistance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction NYHA Class III-IV</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment arm (mirabegron)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.&#xD;
Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).</description>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stable heart failure NYHA class III-IV on ischemic or non-ischemic basis&#xD;
&#xD;
          2. Left ventricular ejection fraction (LVEF) &lt; 35% as assessed by cardiac CT&#xD;
&#xD;
          3. NT proBNP &gt; 1000 pg/ml&#xD;
&#xD;
          4. On optimised evidence-based pharmacological HF treatment stable ≥2 weeks with no&#xD;
             current plan for changing HF therapy. The therapy must include a beta-blocker.&#xD;
&#xD;
          5. No change in diuretics ≤1 week&#xD;
&#xD;
          6. No admittances to hospital for treatment with intravenously administered positive&#xD;
             inotropic agents ≤ 4 weeks.&#xD;
&#xD;
          7. &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute myocardial infarction (AMI) or revascularisation &lt; 3 month ago&#xD;
&#xD;
          2. Uncorrected significant primary obstructive valve disease&#xD;
&#xD;
          3. Planned major surgery including cardiac revascularisation&#xD;
&#xD;
          4. Hemodynamically significant obstructive cardiomyopathy&#xD;
&#xD;
          5. Acute myocarditis or constrictive pericarditis&#xD;
&#xD;
          6. Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference&#xD;
             level) or renal (GFR&lt; 30 ml/min/1,73 m2) diseases&#xD;
&#xD;
          7. Heart failure due to uncorrected thyroid disease&#xD;
&#xD;
          8. Cardiac mechanical support&#xD;
&#xD;
          9. &lt; 6 months after CRT&#xD;
&#xD;
         10. Uncontrolled hypotension (defined as symptomatic systolic blood pressure &lt; 80 mmHg) -&#xD;
             or hypertension (defined as systolic at 180 mmHg or above and/or diastolic blood&#xD;
             pressure at 110 mmHg or below)&#xD;
&#xD;
         11. Unable to give informed consent&#xD;
&#xD;
         12. Reduced compliance&#xD;
&#xD;
         13. All women of child bearing potential will be required to use adequate contraception&#xD;
&#xD;
         14. Pregnant or lactating women&#xD;
&#xD;
         15. Treatment with a tricyclic antidepressant or CYP2D6 substrates other than&#xD;
             beta-blockers or treatment with digoxin.&#xD;
&#xD;
         16. Known allergy to iodine containing contrast&#xD;
&#xD;
         17. Estimated GFR &lt; 30 ml/min/1.73 m2&#xD;
&#xD;
         18. Congenital or drug induced QT prolongation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Bundgaard H, Axelsson A, Hartvig Thomsen J, Sørgaard M, Kofoed KF, Hasselbalch R, Fry NA, Valeur N, Boesgaard S, Gustafsson F, Køber L, Iversen K, Rasmussen HH. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail. 2017 Apr;19(4):566-575. doi: 10.1002/ejhf.714. Epub 2016 Dec 18.</citation>
    <PMID>27990717</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Henning Bundgaard</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

